

June 12, 2008

## **Geron says stem cell treatment does well in early tests**

A **Geron Corp.** heart failure treatment derived from human embryonic stem cells did well in early tests of how likely it is to avoid being attacked by a patient's immune system.

Menlo Park-based Geron (NASDAQ: GERN) presented data on the studies at an annual meeting of the International Society for Stem Cell Research in Philadelphia this week.

Ultimately, treatments like Geron's are meant to reduce the need for whole-organ transplants, which require recipients to take drugs to suppress their own immune systems. Such stem cell treatments provoke a minimal response from the immune system, Geron said in its presentation.

Geron, led by President and CEO Dr. Thomas Okarma, is also developing similar human embryonic stem cell treatments for liver disease and also drugs aimed at cancer and diabetes.

*San Francisco Business Times*